JP3517274B2 - Skin composition - Google Patents
Skin compositionInfo
- Publication number
- JP3517274B2 JP3517274B2 JP13105994A JP13105994A JP3517274B2 JP 3517274 B2 JP3517274 B2 JP 3517274B2 JP 13105994 A JP13105994 A JP 13105994A JP 13105994 A JP13105994 A JP 13105994A JP 3517274 B2 JP3517274 B2 JP 3517274B2
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- human
- extract
- test
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】
【０００１】
【産業上の利用分野】 本発明は植物由来のヒトインタ
ーフェロン誘発物質及びそれを含有する皮膚組成物に関
し、医療用から一般大衆向けに用いることができる。
【０００２】
【従来の技術】 インターフェロン（以下 IFN と略記
する）はもともと抗ウイルス作用を持つサイトカインと
して同定されたが、現在ではきわめて多くの生物活性を
有することが明らかにされている。その中で臨床的にも
っとも期待されているのが抗腫瘍活性であり、Hairy ce
ll leukemia や慢性骨髄性白血病、悪性黒色腫等に高い
効果が認められている。この他にも IFN は様々な臨床
応用が試みられており、アトピー性皮膚炎に対する IFN
の使用もその一例である。
【０００３】しかし IFN には種特異性があるため、ヒ
トにはヒト IFN を処方しなければならない。そこで臨
床的にはリコンビナントのヒト IFN が用いられている
が、リコンビナントを用いることに起因する副作用や、
ヒト由来の細胞から産生された天然型の IFN ほどの効
果が得られない等の問題があった。
【０００４】これらの問題点を解決する手段として、IF
N そのものではなく IFN の誘発物質を投与することに
よって生体に IFN を産生させることが考えられるが、
このためには投与する IFN の誘発物質に高い安全性が
要求される。
【０００５】動物ウイルス以外の天然型ヒト IFN の誘
発物質としては poly I:C や LPS 等が知られている
が、これらは人体にとって無害であるとは言えない。ま
た、植物由来の IFN 誘発物質に関する報告（特開昭62-
19525 等）もなされてはいるが、IFN の産生細胞にマウ
スやウサギ由来の細胞を用いているため、これらがヒト
に於いても種特異性のある IFN を産生させ得るかどう
かは不明である。また、これらの報告では IFN 力価の
測定にバイオアッセイを用いているため、サンプル中に
含まれるかもしれない TNF の様な抗ウイルス活性を示
すサイトカイン等の影響を受けている可能性もあり、こ
れら IFN 誘発物質の効果には疑問が残る。
【０００６】
【発明が解決しようとする課題】 そこで、ヒト由来の
細胞に対する安全性の高い IFN 誘発物質が望まれてい
た。またこの IFN の誘発物質を皮膚組成物等の形態で
投与することにより皮膚内に IFN を産生させれば、ウ
イルスに起因するヘルペスや悪性黒色腫等の腫瘍に効果
を発揮するだけでなく、アトピー性皮膚炎等の炎症によ
る肌荒れの改善や、IFN の持つ生物活性、例えばヒアル
ロン酸産生促進作用による真皮マトリックス成分の増
加、コラゲナーゼ産生促進作用（ M. R.Duncan et al.
; Arch. Dermatol. Res., 281, 11, 1989 ）による真
皮中の古いコラーゲンの代謝促進等により、水々しく弾
力のある健康な肌をつくることが期待される。
【０００７】そこで本発明の目的は、請求項１のヒトイ
ンターフェロン誘発物質が、黄連 、骨砕補、金果欖、
小花棘豆、蒙古久苓草、細辛、白茨、苦豆子、香附、問
荊、陳皮、現証拠、乾姜、桃仁、黄ごん、辛夷、防己、
ウコン、厚朴、紅花、椎茸、セロリ及びバナナを用いる
ことにより安全性の高い天然型ヒト IFN 誘発物質を提
供すること、並びにその有効な投与方法として該物質を
含有することを特徴とする皮膚組成物を提供することに
ある。
【０００８】
【課題を解決するための手段】 安全性の高い天然型ヒ
ト IFN 誘発物質を提供するため、従来から良く知られ
ている各種天然物試料のヒト末梢血単核球に対する IFN
誘発能試験を鋭意行い、黄連、骨砕補、金果欖、小花
棘豆、蒙古久苓草、細辛、白茨、苦豆子、香附、問荊、
陳皮、現証拠、乾姜、桃仁、黄ごん、辛夷、防己、ウコ
ン、厚朴、紅花、椎茸、セロリ及びバナナの抽出物にヒ
ト IFN 誘発活性があることを見い出し、本発明を為す
に至った。
【０００９】ヒト IFN 誘発物質の抽出方法は特に限定
しないが、その抽出溶媒としては水やリン酸緩衝液の様
な公知の緩衝塩類溶液、また、メタノール、エタノー
ル、プロパノール、ブタノール、アセトンの様な有機溶
媒の適当な濃度、及びこの２種以上を混合して得られる
溶媒を用いることができる。この場合、加熱抽出を行う
ことにより抽出効率を上げることができる。尚、緩衝塩
類溶液や有機溶媒は例示した種類に限定されるものでは
ない。
【００１０】
【実施例】 本発明のヒト IFN 誘発物質は、ヒト由来
の細胞に対する IFN 誘発活性を有する。この効果は、
以下の実験及び試験によって裏付けられる。
【００１１】実験例１ 乾燥した骨砕補１kgを粉砕し、
これに水10Lを加えて60℃で24時間抽出を行った。濾過
により抽出液と残渣に分け、残渣に水10Lを加えて再度6
0℃で24時間抽出を行った後、濾過により得た抽出液を
先の抽出液と合わせた。こうして得られた抽出液を減圧
下で濃縮した後、凍結乾燥することにより骨砕補水抽出
物約200gを得た。
【００１２】試験例１ 上記骨砕補水抽出物を試験試料
とし、下記試験法によりヒト末梢血単核球に対する IFN
誘発能試験を行った。
【００１３】健常人より末梢血をヘパリン加採血し、Fi
coll-paque を用いて常法により末梢血単核球を得た。
これを、FBS を10％含む RPMI1640培地を用いて１×106
cells/mlになるように調整した。この細胞浮遊液１ml
に、実験例１に記載した方法に準じて得られたヒト IFN
誘発物質を所定量添加し、37℃で48時間培養した。培
養液を遠心処理して上澄み液を回収し、その IFN 活性
を測定した。IFN-α誘発の陽性対照にはセンダイウイル
ス（以下 HVJ と略記する）を、IFN-γ誘発の陽性対照
にはフィトヘマグルチニン（以下 PHA と略記する）を
用いた。
【００１４】IFN 活性の測定には、抗ヒト白血球由来天
然型 IFN-αウマポリクローナル抗体或いは抗ヒト白血
球由来天然型 IFN-γウサギポリクローナル抗体を用い
た蛍光免疫測定法を使用した。バイオアッセイではなく
免疫測定法を用いることにより、TNF の様な抗ウイルス
活性を示すサイトカイン等の影響を受けることなく、IF
N のみを測定することができる。
【００１５】表１は、実験例１で得た試験試料を表１に
示した濃度になるように添加したときの試験結果であ
る。表中の IFN 活性は、国際単位で示した。表１の結
果から、骨砕補水抽出物にヒト IFN の誘発活性が認め
られた。
【表１】
【００１６】試験例２ 黄連、金果欖、小花棘豆、蒙古
久苓草、細辛、白茨、苦豆子、香附、問荊、陳皮、現証
拠、乾姜、桃仁、黄ごん、辛夷、防己、ウコン、厚朴、
紅花、椎茸の乾燥物を実験例１に記載した方法に準じて
処理し、これらを試験試料として試験例１に記載した方
法に準じてヒト末梢血単核球に対する IFN 誘発能試験
を行った。
【００１７】表２は、試験例２に於いて、実験例１に記
載した方法に準じて処理して得た各試験試料を表２に示
した濃度になるように添加したときの試験結果である。
表２の結果から、黄連、金果欖、小花棘豆、蒙古久苓
草、細辛、白茨、苦豆子、香附、問荊、陳皮、現証拠、
乾姜、桃仁、黄ごん、辛夷、防己、ウコン、厚朴、紅
花、椎茸の各抽出物にヒト IFN の誘発活性が認められ
た。
【表２】
【００１８】実験例２ 成熟した生のバナナ果実１kgを
ミキサーにかけ、圧搾によりバナナ果汁を得た。このと
き、圧搾しやすくするために水を適宜加えても良い。こ
のバナナ果汁を凍結乾燥することにより、バナナ抽出物
約50gを得た。
【００１９】試験例３ 上記バナナ抽出物及び、生のセ
ロリを実験例２に記載した方法に準じて処理して得たセ
ロリ抽出物を試験試料として、試験例１に記載した方法
に準じてヒト末梢血単核球に対する IFN 誘発能試験を
行った。
【００２０】表３は、バナナ抽出物或いはセロリ抽出物
を表３に示した濃度になるように添加したときの試験結
果である。表３の結果から、バナナ及びセロリの抽出物
にヒト IFN の誘発活性が認められた。
【表３】
【００２１】次に、本発明のヒト IFN 誘発物質を含有
する化粧料の処方例を示す。本発明に配合する本発明の
ヒト IFN 誘発物質の配合量は、特に限定しないが通常
0.001〜20.00 重量％（以下 wt% と略記する）が用いら
れる。製品への臭いや着色の影響及び肌への効果を考慮
すると、0.1〜5.0 wt% が望ましい。この処方例により
本発明の皮膚組成物が何らの制限を受けるものではな
い。
【００２２】
処方例１ クリーム ( wt % )
水相 ：ジプロピレングリコール ２.０
グリセリン ３.０
精製水 ３０.０
実験例１の骨砕補抽出物 １.０
油相 ：セタノール ８.０
ホホバ油 ５.０
スクワラン ３７.５
ミツロウ ６.０
乳化剤：親油性モノステアリン酸グリセリン ２.０
ホ゜リオキシエチレンソルヒ゛タンモノラウリン酸エステル ( 20. E. O. ) ２.０
香料 適量
防腐剤 適量
【００２３】製法 水相の成分を混合し、加熱して70℃
に保ち水相部とする。一方、他の成分を混合し、加熱溶
解して70℃に保ち油相部とする。この油相部を前述の水
相部に加えて乳化を行い、30℃まで冷却して製品のクリ
ームを得る。
【００２４】
処方例２ クリーム状ファンデーション ( wt % )
顔料 ：酸化チタン ８.０
カオリン ５.０
タルク ２.０
ベントナイト １.０
着色顔料 適量
水相 ：トリエタノールアミン １.２
ソルビット ３.０
精製水 ５０.０
実験例２のバナナ抽出物 １.０
油相 ：ステアリン酸 ５.０
モノステアリン酸グリセリン ２.５
セタノール １.０
モノラウリン酸プロピレングリコール ３.０
スクワラン ７.０
オクタン酸セチル ８.０
香料 適量
防腐剤 適量
【００２５】製法 水相を調製し、これに混合した顔料
を加えて分散させた後、75℃に加熱する。油相を調製
し、80℃に加熱する。油相を水相に攪拌しながら加えて
乳化した後に冷却し、香料を加え、30℃まで冷却して製
品を得る。
【００２６】
処方例３ 口紅 ( wt % )
基剤 ：細辛抽出物 １.０
ヒマシ油 ４５.０
ヘキサデシルアルコール ２５.０
ミツロウ ５.０
キャンデリラロウ ７.０
カルナバロウ ６.０
ラノリン ４.０
色材 ：酸化チタン ２.０
着色料 適量
香料 適量
【００２７】製法 基剤原料を加熱融解し、色材を加え
てロールミルで練り、均一に色材を分散させる。その後
再融解して香料を加え、型に流し込んで製品の口紅を得
る。
【００２８】
【発明の効果】 本発明の効果を明らかにするため、人
による使用試験を行った。すなわち、
【００２９】試験例４ 処方例１に示したクリームとそ
こから本発明による IFN 誘発物質を除いたクリーム
を、顔面左右半顔ずつに通常通りの使用方法で10名のパ
ネラーに１ヶ月間連続塗布し、その後肌のはり、つや、
水々しさ、滑らかさの４項目について官能評価を行っ
た。
【００３０】表４に、試験例４で実施した官能評価の評
価基準を示した。肌のはり、つや、水々しさ、滑らかさ
のそれぞれを、“ほとんどない”の１点から“非常にあ
る”の５点までの５段階評価で表わした。
【表４】
【００３１】表５に、試験例４の結果を示した。表中の
数字は、表４の評価基準に基づいて評価した10名のパネ
ラーの平均点である。表５の結果から明らかなように、
本発明のヒト IFN 誘発物質を含有した化粧料は、対照
品に比べて優れた整肌効果が認められた。
【表５】 Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a plant-derived human interferon-inducing substance and a skin composition containing the same, which can be used for medical purposes and for the general public. [0002] Interferon (hereinafter abbreviated as IFN) was originally identified as a cytokine having an antiviral effect, but has now been found to have an extremely large number of biological activities. Among them, the most anticipated clinically is antitumor activity, and Hairy ce
High effects have been observed for ll leukemia, chronic myelogenous leukemia, malignant melanoma, etc. Various other clinical applications of IFN have been attempted, and IFN has been used for atopic dermatitis.
Is also an example. However, humans must be prescribed human IFN because of the species specificity of IFN. Therefore, recombinant human IFN is used clinically, but there are side effects caused by using recombinant,
There were problems such as that the effect was not as high as that of natural IFN produced from human-derived cells. As a means for solving these problems, an IF
It is conceivable that the body may produce IFN by administering an inducer of IFN instead of N itself.
This requires high safety of the IFN inducer to be administered. [0005] Poly I: C, LPS and the like are known as inducers of natural human IFN other than animal viruses, but they cannot be said to be harmless to the human body. In addition, a report on plant-derived IFN-inducing substances (Japanese Unexamined Patent Publication No.
19525, etc.), but since cells derived from mice and rabbits are used as IFN-producing cells, it is unclear whether they can produce species-specific IFN even in humans. . In addition, since these reports use a bioassay to measure IFN titers, they may be affected by cytokines that exhibit antiviral activity such as TNF that may be contained in the sample, The effects of these IFN inducers remain questionable. [0006] Therefore, there has been a demand for a highly safe IFN-inducing substance for human-derived cells. In addition, if IFN is produced in the skin by administering this inducer of IFN in the form of a skin composition, etc., it will not only exert an effect on tumors such as herpes and malignant melanoma caused by the virus, but also atopy. Improves skin roughness due to inflammation such as atopic dermatitis, increases the biological activity of IFN such as dermal matrix components by promoting hyaluronic acid production, and promotes collagenase production (see MRDuncan et al.
Arch. Dermatol. Res., 281, 11, 1989) is expected to produce fresh, elastic and healthy skin by promoting the metabolism of old collagen in the dermis. Accordingly, an object of the present invention is to provide a human interferon-inducing substance according to claim 1, wherein the human interferon-inducing substance is oren, bone crushing supplement, gold fruit lantern,
Kobana spiny beans, Mongo Koryosa, fine spices, white thorns, bitter beans, katsuki, thorns, chen skin, current evidence, ginger, peaches, yellow beans, spices, self defense,
A skin composition characterized by providing a highly safe natural human IFN-inducing substance by using turmeric, magnolia, safflower, shiitake, celery and banana, and containing the substance as an effective administration method thereof To provide things. Means for Solving the Problems In order to provide a natural human IFN inducer with high safety, IFN against human peripheral blood mononuclear cells in various well-known natural product samples has been conventionally known.
Eagerly conducting inducing ability tests, Oren, Bone Crushing, Kinkalan, Kobana Thorn Beans, Mongo Kureiso, Spicy, White Thorn, Mameko, Katsuki, Intercession,
The present inventors have found that extracts of Chen skin, present evidence, ginger, peach seeds, yellow pepper, spicy, self-defense, turmeric, magnolia, safflower, shiitake mushroom, celery, and banana have human IFN-inducing activity, and led to the present invention. Was. The method of extracting the human IFN-inducing substance is not particularly limited, and the extraction solvent may be a known buffer salt solution such as water or phosphate buffer, or a solvent such as methanol, ethanol, propanol, butanol and acetone. An appropriate concentration of an organic solvent and a solvent obtained by mixing two or more of them can be used. In this case, the extraction efficiency can be increased by performing the heat extraction. In addition, the buffer salt solution and the organic solvent are not limited to the types described above. The human IFN-inducing substance of the present invention has an IFN-inducing activity on human-derived cells. This effect is
This is supported by the following experiments and tests. Experimental Example 1 1 kg of dried bone crusher was crushed,
To this, 10 L of water was added, and extraction was performed at 60 ° C. for 24 hours. Separate the extract and residue by filtration, add 10 L of water to the residue,
After performing extraction at 0 ° C. for 24 hours, the extract obtained by filtration was combined with the above extract. The extract thus obtained was concentrated under reduced pressure, and then freeze-dried to obtain about 200 g of a bone rehydration extract. Test Example 1 The above bone extract rehydration extract was used as a test sample, and IFN against human peripheral blood mononuclear cells was determined by the following test method.
An inducibility test was performed. [0013] Heparin-supplemented peripheral blood is collected from a healthy person, and Fi
Peripheral blood mononuclear cells were obtained by a conventional method using coll-paque.
This was added to 1 × 10 6 using RPMI1640 medium containing 10% FBS.
It was adjusted to cells / ml. 1 ml of this cell suspension
The human IFN obtained according to the method described in Experimental Example 1
A predetermined amount of an inducer was added, and the cells were cultured at 37 ° C. for 48 hours. The culture was centrifuged to recover the supernatant, and its IFN activity was measured. Sendai virus (hereinafter abbreviated as HVJ) was used as a positive control for IFN-α induction, and phytohemagglutinin (hereinafter abbreviated as PHA) was used as a positive control for IFN-γ induction. For the measurement of IFN activity, a fluorescent immunoassay using an anti-human leukocyte-derived natural IFN-α horse polyclonal antibody or an anti-human leukocyte-derived natural IFN-γ rabbit polyclonal antibody was used. By using an immunoassay rather than a bioassay, IFN is not affected by cytokines that exhibit antiviral activity, such as TNF.
Only N can be measured. Table 1 shows the test results when the test sample obtained in Experimental Example 1 was added so as to have the concentration shown in Table 1. IFN activities in the table are shown in international units. From the results shown in Table 1, human IFN-inducing activity was observed in the bone crushing rehydration extract. [Table 1] Test Example 2 Oren, Kinkalan, Kobana Thorn Beans, Mongo Koryosa, Spicy, White Thorn, Mameko, Katsuki, Ishige, Chenhide, Current Evidence, Ginger, Tomon, Yellow Gon , Xinyi, Self-defense, Turmeric, Thick,
Dried safflower and shiitake mushrooms were treated according to the method described in Experimental Example 1, and these were used as test samples to conduct an IFN-inducing ability test on human peripheral blood mononuclear cells according to the method described in Test Example 1. Table 2 shows the test results when each test sample obtained by treating according to the method described in Experimental Example 1 in Test Example 2 was added so as to have the concentration shown in Table 2. is there.
From the results in Table 2, it can be seen that Oren, Kinkalan, Kobana Thorn Beans, Mongo Koryosa, Spicy, White Thorn, Mameko, Katsuki, Qingwei, Chenpi, Current Evidence,
Extracts of ginger, peach tongue, yellow sesame, spicy, self-defense, turmeric, magnolia, safflower and shiitake mushrooms showed human IFN-inducing activity. [Table 2] Experimental Example 2 1 kg of mature raw banana fruit was placed in a mixer and pressed to obtain banana juice. At this time, water may be appropriately added to facilitate the pressing. The banana juice was freeze-dried to obtain about 50 g of a banana extract. Test Example 3 A celery extract obtained by treating the above banana extract and raw celery according to the method described in Experimental Example 2 was used as a test sample, and humans were processed according to the method described in Test Example 1. An IFN inducibility test was performed on peripheral blood mononuclear cells. Table 3 shows the test results when the banana extract or the celery extract was added to the concentration shown in Table 3. From the results shown in Table 3, the banana and celery extracts were found to have human IFN-inducing activity. [Table 3] Next, a formulation example of a cosmetic containing the human IFN-inducing substance of the present invention will be described. The amount of the human IFN-inducing substance of the present invention to be added to the present invention is not particularly limited, but is usually
0.001 to 20.00% by weight (hereinafter abbreviated as wt%) is used. Considering the effects of odor and coloring on the product and the effects on the skin, 0.1 to 5.0 wt% is desirable. The formulation does not impose any restrictions on the skin composition of the present invention. Formulation Example 1 Cream (wt%) Aqueous phase: dipropylene glycol 2.0 glycerin 3.0 Purified water 30.0 Osteoclastic supplement extract of Experimental Example 1 Oil phase: cetanol 8.0 Jojoba oil 5.0 Squalane 37.5 Beeswax 6.0 Emulsifier: lipophilic glyceryl monostearate 2.0 Polyoxyethylene sorbitan monolaurate (20.EO) 2.0 Perfume Appropriate Preservative Appropriate [Preparation method] Mix and heat to 70 ° C
And maintain the aqueous phase. On the other hand, other components are mixed, dissolved by heating, and kept at 70 ° C. to obtain an oil phase. The oil phase is added to the aqueous phase to emulsify, and cooled to 30 ° C. to obtain a cream of the product. Formulation Example 2 Creamy foundation (wt%) Pigment: Titanium oxide 8.0 Kaolin 5.0 Talc 2.0 Bentonite 1.0 Color pigment Appropriate amount Water phase: Triethanolamine 1.2 Sorbit 3.0 Purified water 50.0 Banana extract of Experimental Example 2 1.0 Oil phase: Stearic acid 5.0 Glycerin monostearate 2.5 Cetanol 1.0 Propylene glycol monolaurate 3.0 Squalane 7.0 Cetyl octanoate 8.0 Fragrance Appropriate amount Preservative Appropriate amount Preparation Method An aqueous phase is prepared, mixed with a pigment, dispersed, and then heated to 75 ° C. Prepare the oil phase and heat to 80 ° C. The oil phase is added to the aqueous phase while stirring to emulsify, then cooled, flavor is added, and cooled to 30 ° C. to obtain the product. Formulation Example 3 Lipstick (wt%) Base: Spicy extract 1.0 Castor oil 45.0 Hexadecyl alcohol 25.0 Beeswax 5.0 Candelilla wax 7.0 Carnauba wax 6.0 Lanolin 4.0 Coloring material: Titanium oxide 2.0 Coloring agent Appropriate amount Fragrance Appropriate amount Manufacturing method The base material is heated and melted, and the coloring material is added and kneaded with a roll mill to uniformly disperse the coloring material. Then re-melt, add fragrance and pour into mold to get product lipstick. Effects of the Invention In order to clarify the effects of the present invention, use tests by humans were performed. Test Example 4 The cream shown in Formulation Example 1 and the cream from which the IFN-inducing substance according to the present invention was removed were applied to 10 panelists for 1 month on the left, right and right faces of the face for one month. Continuous application, then skin glue, shine,
Sensory evaluation was performed on four items of freshness and smoothness. Table 4 shows the evaluation criteria for the sensory evaluation performed in Test Example 4. Each of the skin shine, gloss, freshness, and smoothness was represented by a five-point scale from 1 point of "almost no" to 5 points of "very much". [Table 4] Table 5 shows the results of Test Example 4. The numbers in the table are the average scores of 10 panelists evaluated based on the evaluation criteria in Table 4. As is clear from the results in Table 5,
The cosmetic containing the human IFN-inducing substance of the present invention exhibited an excellent skin conditioning effect as compared with the control product. [Table 5]
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭60−258104（ＪＰ，Ａ) 特開 平６−256205（ＪＰ，Ａ) 特開 平６−183986（ＪＰ，Ａ) 特開 平７−277944（ＪＰ，Ａ) 特開 平７−61920（ＪＰ，Ａ) 特開 平７−187949（ＪＰ，Ａ) 特開 昭57−185210（ＪＰ，Ａ) 特開 平２−111710（ＪＰ，Ａ) 特開 昭64−61415（ＪＰ，Ａ) 特開 平３−190809（ＪＰ，Ａ) 特開 昭63−57510（ＪＰ，Ａ) 特開 昭62−142120（ＪＰ，Ａ) 特開 平６−122619（ＪＰ，Ａ) 特開 昭63−303908（ＪＰ，Ａ) 特開 昭60−109509（ＪＰ，Ａ) 特開 昭62−234006（ＪＰ，Ａ) 特開 平４−82816（ＪＰ，Ａ) 特開 平５−246874（ＪＰ，Ａ) 特開 平４−82814（ＪＰ，Ａ) 特開 平６−24937（ＪＰ，Ａ) 特開 平５−286824（ＪＰ，Ａ) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 7/00 - 7/50 A61K 35/78 ──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-60-258104 (JP, A) JP-A-6-256205 (JP, A) JP-A-6-183986 (JP, A) JP-A-7- 277944 (JP, A) JP-A-7-61920 (JP, A) JP-A-7-187949 (JP, A) JP-A-57-185210 (JP, A) JP-A-2-111710 (JP, A) JP-A-64-61415 (JP, A) JP-A-3-190809 (JP, A) JP-A-63-5710 (JP, A) JP-A-62-142120 (JP, A) JP-A-6-1222619 JP-A-63-303908 (JP, A) JP-A-60-109509 (JP, A) JP-A-62-234006 (JP, A) JP-A-4-82816 (JP, A) JP-A-5-246874 (JP, A) JP-A-4-82814 (JP, A) JP-A-6-24937 (JP, A) JP-A-5-286824 ( P, A) (58) investigated the field (Int.Cl. 7, DB name) A61K 7/00 - 7/50 A61K 35/78
Claims (1)
小花棘豆、蒙古久苓草、防己及びバナナから抽出される
物質を、０．１〜５．０ｗｔ％配合することを特徴とす
る化粧料。(57) [Claim 1] As a human interferon inducer,
A cosmetic comprising 0.1 to 5.0% by weight of a substance extracted from pea thorn beans, Mongo Kureiso, self-defense and banana.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13105994A JP3517274B2 (en) | 1994-05-20 | 1994-05-20 | Skin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13105994A JP3517274B2 (en) | 1994-05-20 | 1994-05-20 | Skin composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07309713A JPH07309713A (en) | 1995-11-28 |
| JP3517274B2 true JP3517274B2 (en) | 2004-04-12 |
Family
ID=15049048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13105994A Expired - Lifetime JP3517274B2 (en) | 1994-05-20 | 1994-05-20 | Skin composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3517274B2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2324399A1 (en) * | 1998-03-19 | 1999-09-23 | Sunstar Inc. | A food composition and use thereof for lowering human cholesterol levels |
| KR20010113435A (en) | 2000-06-16 | 2001-12-28 | 야기타 카즈코 | Cancer therapeutic agent |
| KR20030025975A (en) * | 2001-09-24 | 2003-03-31 | 주식회사 콧데 | Skin immune modulating composition containing magnolia extracts as active ingredients |
| RU2217196C2 (en) | 2002-02-28 | 2003-11-27 | Небольсин Владимир Евгеньевич | Method for induction of cells differentiation |
| EP1495763B1 (en) * | 2002-04-15 | 2009-03-18 | Tetsuo Santo | Therapeutic cream for dermatitis |
| AU2002248029A1 (en) * | 2002-04-15 | 2003-10-27 | Tetsuo Santo | Therapeutic lotion for dermatitis |
| WO2003086435A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Cleanser |
| US20040223942A1 (en) * | 2003-03-06 | 2004-11-11 | Kao Corporation | Skin aging-preventing or improving agent |
| JP2006117552A (en) * | 2004-10-19 | 2006-05-11 | Hayashibara Biochem Lab Inc | Skin care preparation for photo-aging prevention |
| JP2007238559A (en) * | 2006-03-10 | 2007-09-20 | Nagoya City Univ | Immature dendritic cell-activating agent and use thereof |
| KR101098581B1 (en) * | 2009-01-09 | 2011-12-26 | 서울대학교산학협력단 | Composition for Improving Inflammatory Disorder Using ABH Antigen |
| JP2012171933A (en) * | 2011-02-23 | 2012-09-10 | Kao Corp | Aromatase activator |
| JP2016190814A (en) * | 2015-03-31 | 2016-11-10 | 株式会社東洋新薬 | Calcium permeation promoter |
| CN105031355A (en) * | 2015-08-18 | 2015-11-11 | 成都市飞龙水处理技术研究所 | Oral administration medicine for treating autosensitization dermatitis and preparation method thereof |
| TWI670059B (en) | 2017-11-22 | 2019-09-01 | 大江生醫股份有限公司 | Uses of gallocatechin |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57185210A (en) * | 1981-05-09 | 1982-11-15 | Osaka Chem Lab | Cosmetic composition containing oren |
| JPS60109509A (en) * | 1983-11-16 | 1985-06-15 | Narisu Keshohin:Kk | Beautifying and whitening cosmetic |
| JPS60258104A (en) * | 1984-06-06 | 1985-12-20 | Inahata Koryo Kk | Cosmetic composition having moisture retention |
| JPS62142120A (en) * | 1985-12-17 | 1987-06-25 | Hitoshi Nagaoka | Beauty wash composition for remedy of atopic dermatitis |
| JPS62234006A (en) * | 1986-04-02 | 1987-10-14 | Shiseido Co Ltd | External drug for skin |
| JPS6357510A (en) * | 1986-08-27 | 1988-03-12 | Shiseido Co Ltd | Cosmetic |
| JPS63303908A (en) * | 1987-06-04 | 1988-12-12 | Tsuneo Aranami | Cosmetic composition and additive |
| JPH0637377B2 (en) * | 1987-08-29 | 1994-05-18 | サンスタ−株式会社 | Cosmetics |
| JPH02111710A (en) * | 1988-10-20 | 1990-04-24 | Akio Fujikawa | Cosmetic composition |
| JP2969274B2 (en) * | 1989-12-21 | 1999-11-02 | 株式会社資生堂 | Anti-roughening agent |
| JP3107583B2 (en) * | 1991-03-04 | 2000-11-13 | 義秀 萩原 | Skin and hair cosmetics |
| JP2698468B2 (en) * | 1990-07-23 | 1998-01-19 | 御木本製薬株式会社 | Scrub face wash |
| JPH0791179B2 (en) * | 1990-07-23 | 1995-10-04 | 御木本製薬株式会社 | Whitening cosmetics |
| JP3315427B2 (en) * | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | Dermatitis treatment |
| JPH05286824A (en) * | 1992-04-08 | 1993-11-02 | Kanegafuchi Chem Ind Co Ltd | Liposome-containing cosmetic |
| JP3536111B2 (en) * | 1992-06-29 | 2004-06-07 | 株式会社ナリス化粧品 | Mucopolysaccharide fragmentation inhibitor and cosmetic |
| JPH06183986A (en) * | 1992-12-22 | 1994-07-05 | Kunisaku Ueda | Colloidal solution for treating intractable dermatitis and its production |
| JP3254567B2 (en) * | 1993-03-08 | 2002-02-12 | 山之内製薬株式会社 | Method for producing physiologically active substance from plant tissue and composition containing this substance |
| JP2651992B2 (en) * | 1993-08-24 | 1997-09-10 | 株式会社粘土科学研究所 | Bath additive |
| JPH07187949A (en) * | 1993-12-27 | 1995-07-25 | Chiba Seifun Kk | Cosmetic |
| JP3862765B2 (en) * | 1994-04-11 | 2006-12-27 | 株式会社ナリス化粧品 | Melanin inhibitor |
-
1994
- 1994-05-20 JP JP13105994A patent/JP3517274B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07309713A (en) | 1995-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3517274B2 (en) | Skin composition | |
| JP3759162B2 (en) | Bioactive products derived from peat, and pharmaceutical and cosmetic compositions containing the bioactive products | |
| KR100982883B1 (en) | Cosmetic composition comprising mixture extract and preparation thereof | |
| EP1779862A1 (en) | Erythropoietin for stimulating endothelial progenitor cells | |
| US7927634B2 (en) | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of Angelica sinensis, and methods of preparation thereof | |
| KR20210066750A (en) | Novel use of milk exosome | |
| CN115340592B (en) | Active peptide and related application thereof | |
| KR102016164B1 (en) | Whitening emulsion cosmetic composition containing a vitamin tree fruit extract and method for manufacturing the same | |
| JP2000044485A (en) | Active oxygen species scavenger and skin cosmetic | |
| JP2002212087A (en) | Skin care preparation | |
| JPH05163135A (en) | Beautifying cosmetic composition | |
| KR102534797B1 (en) | Preparation method of nanoparticles containing anemarrhena asphodeloides extract, polydeoxyribonucleotide and physiologically active materials and cosmetic composition comprising the same | |
| KR100373776B1 (en) | A Composition for Cosmetics | |
| JPS62179587A (en) | Antioxidant comprising onion as main starting material | |
| KR102374382B1 (en) | topical composition comprising the extract of combined herbs comprising Longanae Arillus for TSLP inhibition and for the treatment or alleviation of skin inflammatory disease | |
| JP2002275081A (en) | Skin care preparation | |
| KR20000069310A (en) | Extracellular matrix production promoter | |
| KR20180101125A (en) | Cosmetic composition for skin whitening and improving skin wrinkle comprising horse oil and Rumex acetosella L. extracts | |
| KR102034436B1 (en) | Composition For Treating And Preventing Atopic Dermatitis Comprising Ternstroemia kwangtungensis Merr. Extracts | |
| JPH10109924A (en) | Beautifying and whitening cosmetic | |
| JP2003335625A (en) | Skin care preparation for external use | |
| JP3464038B2 (en) | Collagen synthesis promoter | |
| JP2002037709A (en) | Skin care preparation | |
| KR102431445B1 (en) | Method for manufacturing cream-type cosmetic product containing grub powder | |
| JP3408339B2 (en) | Cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040120 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040123 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090130 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100130 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110130 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110130 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120130 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130130 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130130 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |